Efficacy and safety of MYL‐1501D versus insulin glargine in people with type 1 diabetes mellitus: Results of the INSTRIDE 3 phase 3 switch study

• Published in: Diabetes, obesity & metabolism Vol. 22; no. 3; pp. 365 - 372
• Main Authors: Blevins, Thomas C., Barve, Abhijit, Raiter, Yaron, Aubonnet, Patrick, Athalye, Sandeep, Sun, Bin, Muniz, Rafael
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01.03.2020; Wiley Subscription Services, Inc
• Subjects: biosimilar; Biosimilar Pharmaceuticals; Blood Glucose; Diabetes; Diabetes mellitus (insulin dependent); Diabetes Mellitus, Type 1 - drug therapy; Glycated Hemoglobin A - analysis; Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents - adverse effects; Immunogenicity; Insulin; insulin glargine; Insulin Glargine - adverse effects; Obesity; Original; Safety; switch; type 1 diabetes; type 1 diabetes; insulin glargine; biosimilar; switch
• ISSN: 1462-8902; 1463-1326
• DOI: 10.1111/dom.13904

Aims To assess the efficacy, insulin dose, safety and immunogenicity when people with type 1 diabetes mellitus switched between MYL‐1501D and reference insulin glargine (Lantus®; Sanofi‐Aventis US LLC, Bridgewater, New Jersey). Materials and methods Eligible participants from INSTRIDE 1 who completed 52 weeks of reference insulin glargine treatment were randomized 1:1 to the reference sequence (n = 63; reference insulin glargine for 36 weeks) or to the treatment‐switching sequence (n = 64; MYL‐1501D [weeks 0–12], reference insulin glargine [weeks 12–24] and MYL‐1501D [weeks 24–36]). Change in glycated haemoglobin (HbA1c) from baseline to week 36 was the primary efficacy endpoint used to demonstrate equivalence between the two treatment sequences. Secondary endpoints included: change in fasting plasma glucose (FPG), self‐monitored blood glucose (SMBG) and insulin dose; immunogenicity; and adverse events, including hypoglycaemia. Results Mean changes in HbA1c (least squares [LS] mean [SE]) from baseline to week 36 were −0.05 (0.032) and −0.06 (0.034) for the treatment‐switching and reference sequences, respectively (LS mean difference 0.01 [95% CI −0.085 to 0.101]). Treatment sequences were comparable in terms of secondary endpoints, including FPG, SMBG and insulin dose, and the safety and immunogenicity profiles of the two sequences were similar. Conclusions Switching participants between MYL‐1501D and reference insulin glargine demonstrated equivalent efficacy and similar safety and immunogenicity, showing that people taking reference insulin glargine can safely switch to MYL‐1501D.